Nivolumab for advanced non-small cell lung cancer: An evaluation of a phase III study

Expert Review of Anticancer Therapy

Volumn 16, Issue 2, 2016, Pages 165-167

  Ulmeanu, Ruxandra ^a,b   Antohe, Ileana ^c   Anisie, Ecaterina ^c   Antoniu, Sabina ^c  

^a Marius Nasta Institute of Pulmonology Bucharest   (Romania)

^b UNIVERSITY OF ORADEA   (Romania)

^c GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

lung cancer; monoclonal antibody; Nivolumab; PD 1

Indexed keywords

DOCETAXEL; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; ASTHMA; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; HUMAN; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84957427285     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2016.1127760     Document Type: Article

References (13)

1. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5 Suppl): e1S-29S.
2. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015; 11 (9): 1307-1326.
3. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015; 33 (17): 1974-1982.
4. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12 (4): 252-264.
5. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015; 33 (18): 2004-2012.
6. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366 (26): 2455-2465.
7. Administration, F.a.D. FDA expands approved use of Opdivo to treat lung cancer. 2015; Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm.
8. Agency EM. Nivolumab BMS. 2015; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003840/human-med-001887.jsp&mid=WC0b01ac058001d124.
9. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373 (2): 123-135.
10. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015; 16 (3): 257-265.
11. Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2015; 33 (15-suppl): LBA109.
12. Sundar R, Soong R, Cho BC, et al. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer. 2014; 85 (2): 101-109.
13. Zhang Y, Wang L, Li Y, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther. 2014; 7: 567-573.